We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Advances Manganese-Based MRI Agent to Phase 3 After Positive Data
Read MoreHide Full Article
Key Takeaways
GEHC's mangaciclanol met its Phase 2 primary endpoint, supporting advancement into Phase 3 of the trial.
GEHC selected a 0.1 mmol/kg dose for Phase 3 after results showed comparable imaging to gadobutrol.
Mangaciclanol could address gadolinium retention and supply concerns, tapping into 65M annual MRI procedures.
GE HealthCare Technologies Inc. (GEHC - Free Report) announced positive Phase 2 results for investigational manganese-based MRI contrast agent, mangaciclanol, supporting its advancement into Phase 3 of the LUMINA clinical trial. The results mark an important milestone in the company's efforts to expand its imaging agent portfolio with next-generation contrast media.
The advancement of mangaciclanol into Phase 3 strengthens GEHC's long-term growth prospects by potentially opening up a new opportunity in the MRI contrast media market. If approved, the agent could provide an alternative to existing gadolinium-based contrast agents, addressing concerns around tissue retention, supply chain dependence and environmental impact. Successful development and commercialization could help GEHC strengthen its competitive position in Pharmaceutical Diagnostics and capture a share of the sizable contrast-enhanced MRI market.
GEHC Stock Trend Following the News
Shares of GEHC have gained more than 2% since the announcement on Tuesday. Year to date, the stock has inched down 0.2% compared with the industry’s 16.4% decline. However, the S&P 500 has risen 3.7% during the same timeframe.
The advancement of mangaciclanol into Phase 3 could strengthen GEHC's long-term growth prospects by expanding its Pharmaceutical Diagnostics portfolio with a potentially differentiated MRI contrast agent. If approved, mangaciclanol could address growing concerns associated with gadolinium-based agents, including tissue retention, supply chain vulnerabilities and environmental impact, positioning GEHC to capitalize on demand for safer and more sustainable imaging solutions.
With approximately 65 million gadolinium-enhanced MRI procedures performed each year globally, successful commercialization could create a sizable growth opportunity, strengthen the company's competitive positioning in imaging agents and support recurring revenues from its contrast media business.
GEHC currently has a market capitalization of $37.83 billion.
Image Source: Zacks Investment Research
More on the News
The Phase 2 stage of the adaptive Phase 2/3 LUMINA trial was designed to evaluate different doses of mangaciclanol in adults with known or highly suspected central nervous system lesions. Participants received both mangaciclanol and gadobutrol, GEHC's established gadolinium-based contrast agent, with blinded independent readers comparing the resulting images. The study met its primary endpoint of overall diagnostic preference, with both agents demonstrating similar diagnostic preference. Lesion visualization and quantitative imaging findings were also generally comparable. Based on these findings, GEHC selected a dose of 0.1 mmol/kg for Phase 3. The trial is being conducted across clinical sites in the United States, Europe and Asia, with safety evaluation set to continue in the next phase.
Mangaciclanol's potential advantages stem from its manganese-based composition and macrocyclic cage-like structure, which is designed to minimize the possibility of retention in the body. Unlike gadolinium, manganese is an endogenous element naturally present in the body and abundantly available across multiple countries. This could help reduce supply chain vulnerabilities associated with gadolinium mining and processing, which is largely concentrated in China. Its use could also help address environmental concerns related to the excretion of contrast agents into water sources.
The investigational agent has received FDA Fast Track designation, which is intended to expedite the development and review of products addressing significant unmet medical needs. GEHC plans to present preliminary Phase 2 results at the RSNA 2026 meeting. Meanwhile, its Pharmaceutical Diagnostics segment supports approximately 140 million patient procedures annually across imaging modalities, providing an established commercial platform for potential future adoption. However, mangaciclanol remains investigational, and its safety and efficacy have not yet been established by regulatory authorities.
Industry Prospects Favoring the Market
According to Precedence Research, the global diagnostic imaging market size was calculated at $50.12 billion in 2025 and is predicted to increase from $52.55 billion in 2026 to approximately $80.12 billion by 2035, expanding at a CAGR of 4.80% from 2026 to 2035.
The rising awareness of early disease detection is expected to boost the market growth.
Other News
GE HealthCare recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Image: Bigstock
GEHC Advances Manganese-Based MRI Agent to Phase 3 After Positive Data
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) announced positive Phase 2 results for investigational manganese-based MRI contrast agent, mangaciclanol, supporting its advancement into Phase 3 of the LUMINA clinical trial. The results mark an important milestone in the company's efforts to expand its imaging agent portfolio with next-generation contrast media.
The advancement of mangaciclanol into Phase 3 strengthens GEHC's long-term growth prospects by potentially opening up a new opportunity in the MRI contrast media market. If approved, the agent could provide an alternative to existing gadolinium-based contrast agents, addressing concerns around tissue retention, supply chain dependence and environmental impact. Successful development and commercialization could help GEHC strengthen its competitive position in Pharmaceutical Diagnostics and capture a share of the sizable contrast-enhanced MRI market.
GEHC Stock Trend Following the News
Shares of GEHC have gained more than 2% since the announcement on Tuesday. Year to date, the stock has inched down 0.2% compared with the industry’s 16.4% decline. However, the S&P 500 has risen 3.7% during the same timeframe.
The advancement of mangaciclanol into Phase 3 could strengthen GEHC's long-term growth prospects by expanding its Pharmaceutical Diagnostics portfolio with a potentially differentiated MRI contrast agent. If approved, mangaciclanol could address growing concerns associated with gadolinium-based agents, including tissue retention, supply chain vulnerabilities and environmental impact, positioning GEHC to capitalize on demand for safer and more sustainable imaging solutions.
With approximately 65 million gadolinium-enhanced MRI procedures performed each year globally, successful commercialization could create a sizable growth opportunity, strengthen the company's competitive positioning in imaging agents and support recurring revenues from its contrast media business.
GEHC currently has a market capitalization of $37.83 billion.
Image Source: Zacks Investment Research
More on the News
The Phase 2 stage of the adaptive Phase 2/3 LUMINA trial was designed to evaluate different doses of mangaciclanol in adults with known or highly suspected central nervous system lesions. Participants received both mangaciclanol and gadobutrol, GEHC's established gadolinium-based contrast agent, with blinded independent readers comparing the resulting images. The study met its primary endpoint of overall diagnostic preference, with both agents demonstrating similar diagnostic preference. Lesion visualization and quantitative imaging findings were also generally comparable. Based on these findings, GEHC selected a dose of 0.1 mmol/kg for Phase 3. The trial is being conducted across clinical sites in the United States, Europe and Asia, with safety evaluation set to continue in the next phase.
Mangaciclanol's potential advantages stem from its manganese-based composition and macrocyclic cage-like structure, which is designed to minimize the possibility of retention in the body. Unlike gadolinium, manganese is an endogenous element naturally present in the body and abundantly available across multiple countries. This could help reduce supply chain vulnerabilities associated with gadolinium mining and processing, which is largely concentrated in China. Its use could also help address environmental concerns related to the excretion of contrast agents into water sources.
The investigational agent has received FDA Fast Track designation, which is intended to expedite the development and review of products addressing significant unmet medical needs. GEHC plans to present preliminary Phase 2 results at the RSNA 2026 meeting. Meanwhile, its Pharmaceutical Diagnostics segment supports approximately 140 million patient procedures annually across imaging modalities, providing an established commercial platform for potential future adoption. However, mangaciclanol remains investigational, and its safety and efficacy have not yet been established by regulatory authorities.
Industry Prospects Favoring the Market
According to Precedence Research, the global diagnostic imaging market size was calculated at $50.12 billion in 2025 and is predicted to increase from $52.55 billion in 2026 to approximately $80.12 billion by 2035, expanding at a CAGR of 4.80% from 2026 to 2035.
The rising awareness of early disease detection is expected to boost the market growth.
Other News
GE HealthCare recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.